Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(11):1489–1493. doi: 10.1038/bjc.1997.583

Phase I study of gemcitabine using a once every 2 weeks schedule.

J B Vermorken 1, J P Guastalla 1, S R Hatty 1, D E Seitz 1, B Tanis 1, C McDaniels 1, M D Clavel 1
PMCID: PMC2228173  PMID: 9400947

Abstract

Gemcitabine (2',2'-difluorodeoxycytidine) is a novel nucleoside analogue. As part of a series of studies to determine the maximum tolerated dose (MTD) of gemcitabine and the most appropriate schedule, a two-centre phase I study of gemcitabine was undertaken in patients with advanced refractory solid tumours using a once every 2 weeks schedule. Fifty-two patients were entered into the study at 14 different dose levels (40-5700 mg m-2). Weekly evaluations for toxicity were performed and the MTD for this once every 2 weeks schedule was 5700 mg m-2. The dose-limiting toxicity was myelosuppression, with neutropenia being most significant. Other toxicities were nausea, vomiting, fever and asthenia. One minor response was seen in a heavily pretreated breast cancer patient treated at 1200 mg m-2. Preclinical studies suggest that the efficacy of gemcitabine is more schedule than dose related, and it is concluded that this is not the most appropriate dosing schedule for gemcitabine. However, this study demonstrates the safety profile of gemcitabine, as doses over fourfold greater than that recommended for the weekly schedule of 1000 mg m-2 could be tolerated.

Full text

PDF
1489

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese J. L., Grunewald R., Weeks E. A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raber M. N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991 Mar;9(3):491–498. doi: 10.1200/JCO.1991.9.3.491. [DOI] [PubMed] [Google Scholar]
  2. Abratt R. P., Bezwoda W. R., Falkson G., Goedhals L., Hacking D., Rugg T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Aug;12(8):1535–1540. doi: 10.1200/JCO.1994.12.8.1535. [DOI] [PubMed] [Google Scholar]
  3. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Sep;12(9):1821–1826. doi: 10.1200/JCO.1994.12.9.1821. [DOI] [PubMed] [Google Scholar]
  4. Carmichael J., Fink U., Russell R. C., Spittle M. F., Harris A. L., Spiessi G., Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996 Jan;73(1):101–105. doi: 10.1038/bjc.1996.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A. L. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995 Nov;13(11):2731–2736. doi: 10.1200/JCO.1995.13.11.2731. [DOI] [PubMed] [Google Scholar]
  6. Gatzemeier U., Shepherd F. A., Le Chevalier T., Weynants P., Cottier B., Groen H. J., Rosso R., Mattson K., Cortes-Funes H., Tonato M. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996 Feb;32A(2):243–248. doi: 10.1016/0959-8049(95)00444-0. [DOI] [PubMed] [Google Scholar]
  7. Grindey G. B., Hertel L. W., Plunkett W. Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine). Cancer Invest. 1990;8(2):313–313. doi: 10.3109/07357909009017602. [DOI] [PubMed] [Google Scholar]
  8. Lund B., Hansen O. P., Theilade K., Hansen M., Neijt J. P. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994 Oct 19;86(20):1530–1533. doi: 10.1093/jnci/86.20.1530. [DOI] [PubMed] [Google Scholar]
  9. Lund B., Ryberg M., Petersen P. M., Anderson H., Thatcher N., Dombernowsky P. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol. 1994 Nov;5(9):852–853. doi: 10.1093/oxfordjournals.annonc.a059018. [DOI] [PubMed] [Google Scholar]
  10. O'Rourke T. J., Brown T. D., Havlin K., Kuhn J. G., Craig J. B., Burris H. A., Satterlee W. G., Tarassoff P. G., Von Hoff D. D. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer. 1994;30A(3):417–418. doi: 10.1016/0959-8049(94)90276-3. [DOI] [PubMed] [Google Scholar]
  11. Poplin E. A., Corbett T., Flaherty L., Tarasoff P., Redman B. G., Valdivieso M., Baker L. Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study. Invest New Drugs. 1992 Aug;10(3):165–170. doi: 10.1007/BF00877241. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES